Back to top
more

AstraZeneca PLC (AZN)

(Delayed Data from NYSE)

$47.68 USD

47.68
2,223,625

+0.06 (0.13%)

Updated Dec 6, 2019 04:00 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | C Growth | C Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Kinjel Shah

Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

GSK AZN MRK PFE RHHBY JNJ

Zacks Equity Research

AstraZeneca's Lynparza Gets China Nod in First-Line Setting

AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.

GSK AZN RHHBY MRK

Zacks Equity Research

Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.

AZN RHHBY BIIB AUPH

Zacks Equity Research

Immunomedics Resubmits Application for Breast Cancer Drug

Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

AZN RHHBY IMMU CLVS

Zacks Equity Research

Biogen's Lupus Candidate Meets Endpoint in Phase II Study

Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.

AZN ANIK BIIB VRTX

Zacks Equity Research

AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

AZN JNJ AGN ALKS

Zacks Equity Research

Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC

Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.

AZN BMY RHHBY MRK

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC

AstraZeneca's (AZN) Imfinzi, if approved for extensive-stage small cell lung cancer, can cater to a broader lung cancer patient population, which can bring in additional sales.

MRK AZN BMY PFE

Zacks Equity Research

Here's Why Merck's (MRK) Shares Are Up This Year

Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.

MRK AZN PFE AMGN

Kinjel Shah

Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes

The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.

RHHBY MRK PFE AZN ABBV BMY NVS

Zacks Equity Research

AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL

The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.

RHHBY AZN BIIB GILD

Zacks Equity Research

Amarin's Shares Down on Underperform Rating by Oppenheimer

Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

AZN SNY AMRN ACST

Zacks Equity Research

Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

AZN LLY AGN ALKS

Zacks Equity Research

Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.

AZN GSK RHHBY IMGN

Zacks Equity Research

Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

MRK NVO GSK AZN

Zacks Equity Research

AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

MRK AZN NVO GSK

Kinjel Shah

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

ABBV PFE AZN GSK MRK BMY LLY

Zacks Equity Research

Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

SNY GSK AZN REGN

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

BMY AZN BAYRY AVEO

Zacks Equity Research

Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

AZN SNY REGN INO

Zacks Equity Research

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

PFE MRK BMY AZN

Kinjel Shah

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

BMY SNY JNJ AGN AZN NVS NVO

Zacks Equity Research

Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

AGN AZN IRWD CYCN

Zacks Equity Research

BMY or AZN: Which Is the Better Value Stock Right Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY AZN

Zacks Equity Research

Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

AZN AGN MNK MYL